Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia

R. Greco, A. S. Mangione, F. Siani, F. Blandini, M. Vairetti, G. Nappi, G. Sandrini, M. G. Buzzi, C. Tassorelli

Research output: Contribution to journalArticle

Abstract

Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.

Original languageEnglish
Pages (from-to)616-623
Number of pages8
JournalCephalalgia
Volume34
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

Calcitonin Gene-Related Peptide Receptors
Hyperalgesia
Nitroglycerin
Migraine Disorders
Calcitonin Gene-Related Peptide
Pain Measurement
Analgesics
Tail
Trigeminal Nerve
Animal Models
Pain
MK-8825
Therapeutics

Keywords

  • CGRP receptor antagonist
  • hyperalgesia
  • migraine
  • Nitroglycerin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. / Greco, R.; Mangione, A. S.; Siani, F.; Blandini, F.; Vairetti, M.; Nappi, G.; Sandrini, G.; Buzzi, M. G.; Tassorelli, C.

In: Cephalalgia, Vol. 34, No. 8, 2014, p. 616-623.

Research output: Contribution to journalArticle

Greco, R. ; Mangione, A. S. ; Siani, F. ; Blandini, F. ; Vairetti, M. ; Nappi, G. ; Sandrini, G. ; Buzzi, M. G. ; Tassorelli, C. / Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. In: Cephalalgia. 2014 ; Vol. 34, No. 8. pp. 616-623.
@article{ff929e4487d0445483c75fa3a3fcd908,
title = "Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia",
abstract = "Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.",
keywords = "CGRP receptor antagonist, hyperalgesia, migraine, Nitroglycerin",
author = "R. Greco and Mangione, {A. S.} and F. Siani and F. Blandini and M. Vairetti and G. Nappi and G. Sandrini and Buzzi, {M. G.} and C. Tassorelli",
year = "2014",
doi = "10.1177/0333102413517776",
language = "English",
volume = "34",
pages = "616--623",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia

AU - Greco, R.

AU - Mangione, A. S.

AU - Siani, F.

AU - Blandini, F.

AU - Vairetti, M.

AU - Nappi, G.

AU - Sandrini, G.

AU - Buzzi, M. G.

AU - Tassorelli, C.

PY - 2014

Y1 - 2014

N2 - Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.

AB - Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.

KW - CGRP receptor antagonist

KW - hyperalgesia

KW - migraine

KW - Nitroglycerin

UR - http://www.scopus.com/inward/record.url?scp=84902588420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902588420&partnerID=8YFLogxK

U2 - 10.1177/0333102413517776

DO - 10.1177/0333102413517776

M3 - Article

AN - SCOPUS:84902588420

VL - 34

SP - 616

EP - 623

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 8

ER -